Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver Diseases group at VHIR, have received funding for a European research project in...
Read moreDr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society
Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will...
Read moreA new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the highest number of active research projects in Nanomedicine of Europe
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group...
Read moreThe EVO-NANO project will allow testing the behavior of nanoparticles within a tumor
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project...
Read moreApril, Fabry disease awareness month
The Fabry International Network (FIN) association has established the month of April as the «month of Fabry» to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry disease is a...
Read moreDr. Simó Schwartz Jr, appointed editorial Board member of the Precision Nanomedicine journal
In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the...
Read moreThe team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz...
Read moreThe Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or...
Read moreProven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer
The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and...
Read moreNANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for...
Read moreThe EU-NCL network will support a project of nanomedicine for prostate cancer
The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. The project is coordinated by Dr. Simó Schwartz Jr...
Read moreVHIR participates in a European project against Fabry disease
The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, which aims the innovation and improvement in the treatment for Fabry disease, a rare condition...
Read more